| Immune evasion in cancer: Mechanistic basis and therapeutic strategies DS Vinay, EP Ryan, G Pawelec, WH Talib, J Stagg, E Elkord, T Lichtor, ... Seminars in cancer biology 35, S185-S198, 2015 | 1882 | 2015 |
| Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy LF Mager, R Burkhard, N Pett, NCA Cooke, K Brown, H Ramay, S Paik, ... Science 369 (6510), 1481-1489, 2020 | 953 | 2020 |
| Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), 2020 | 947 | 2020 |
| The ectonucleotidases CD 39 and CD 73: novel checkpoint inhibitor targets B Allard, MS Longhi, SC Robson, J Stagg Immunological reviews 276 (1), 121-144, 2017 | 904 | 2017 |
| Consensus guidelines for the detection of immunogenic cell death O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ... Oncoimmunology 3 (9), e955691, 2014 | 877 | 2014 |
| Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis J Stagg, U Divisekera, N McLaughlin, J Sharkey, S Pommey, D Denoyer, ... Proceedings of the National Academy of Sciences 107 (4), 1547-1552, 2010 | 699 | 2010 |
| Allogeneic marrow stromal cells are immune rejected by MHC class I–and class II–mismatched recipient mice N Eliopoulos, J Stagg, L Lejeune, S Pommey, J Galipeau Blood 106 (13), 4057-4065, 2005 | 682 | 2005 |
| Extracellular adenosine triphosphate and adenosine in cancer J Stagg, MJ Smyth Oncogene 29 (39), 5346-5358, 2010 | 672 | 2010 |
| Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy J Stagg, S Loi, U Divisekera, SF Ngiow, H Duret, H Yagita, MW Teng, ... Proceedings of the National Academy of Sciences 108 (17), 7142-7147, 2011 | 581 | 2011 |
| CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer S Loi, S Pommey, B Haibe-Kains, PA Beavis, PK Darcy, MJ Smyth, ... Proceedings of the National Academy of Sciences 110 (27), 11091-11096, 2013 | 559 | 2013 |
| Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs B Allard, S Pommey, MJ Smyth, J Stagg Clinical Cancer Research 19 (20), 5626-5635, 2013 | 520 | 2013 |
| CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis J Stagg, U Divisekera, H Duret, T Sparwasser, MWL Teng, PK Darcy, ... Cancer research 71 (8), 2892-2900, 2011 | 454 | 2011 |
| CD73: a potent suppressor of antitumor immune responses PA Beavis, J Stagg, PK Darcy, MJ Smyth Trends in immunology 33 (5), 231-237, 2012 | 445 | 2012 |
| The adenosine pathway in immuno-oncology B Allard, D Allard, L Buisseret, J Stagg Nature Reviews Clinical Oncology 17 (10), 611-629, 2020 | 431 | 2020 |
| Molecular and translational classifications of DAMPs in immunogenic cell death AD Garg, L Galluzzi, L Apetoh, T Baert, RB Birge, JM Bravo-San Pedro, ... Frontiers in immunology 6, 588, 2015 | 417 | 2015 |
| Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell J Stagg, S Pommey, N Eliopoulos, J Galipeau Blood 107 (6), 2570-2577, 2006 | 412 | 2006 |
| Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers T Gruosso, M Gigoux, VSK Manem, N Bertos, D Zuo, I Perlitch, SMI Saleh, ... The Journal of clinical investigation 129 (4), 1785-1800, 2019 | 385 | 2019 |
| Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors PA Beavis, U Divisekera, C Paget, MT Chow, LB John, C Devaud, ... Proceedings of the National Academy of Sciences 110 (36), 14711-14716, 2013 | 384 | 2013 |
| Targeting cancer-derived adenosine: new therapeutic approaches A Young, D Mittal, J Stagg, MJ Smyth Cancer discovery 4 (8), 879-888, 2014 | 335 | 2014 |
| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 325 | 2015 |